The Sinopharm-backed oncology drug developer has raised series D1 funding in a round led by China Structural Reform Fund Corporation.
China Structural Reform Fund Corporation, a vehicle for conglomerates China Merchants Group and China Chengtong Holding, has led an $80m series D1 round for Canada-headquartered cancer treatment developer Virogin Biotech, DealStreetAsia has reported.
Forebright Capital, GP Capital, Young Label, Champion Ascend and Panlin Capital also took part in the round, which followed about $94m in earlier funding according to Virogin’s website.
Founded in 2015, Virogin is developing oncolytic viruses which are engineered to target and kill tumour cells as well as…
